Zhou Ying, Qiao Yingying, Adcock Ian M, Zhou Jun, Yao Xin
Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Department of Respiratory Medicine, Nanjing Gulou Group Anqing Petrochemical Hospital, 11 Shihua First Road, Anqing, 246002, China.
Lung. 2021 Dec;199(6):629-638. doi: 10.1007/s00408-021-00483-1. Epub 2021 Oct 22.
Found in inflammatory zone 2 (FIZZ2) is associated with lung inflammation. The aim of the study was to investigate the expression and utility of FIZZ2 as a marker for chronic obstructive pulmonary disease (COPD).
Immunohistochemistry was used to detect the expression of FIZZ2 in COPD. The serum concentration of FIZZ2 was measured by enzyme-linked immunosorbent assay and the episodes of acute exacerbations of COPD (AECOPD) in the following year were recorded.
FIZZ2 expression was elevated in bronchial epithelial cells (0.217 ± 0.021 vs 0.099 ± 0.010, p < 0.0001) and negatively correlated with the pulmonary function (FEV1/FVC%) (p = 0.0149) and positively correlated with the smoking index (p = 0.0241). Serum level of FIZZ2 in COPD were significantly higher than that in healthy controls (561.6 ± 70.71 vs 52.24 ± 20.52 pg/ml, p < 0.0001) and increased with the COPD severity. Serum levels of FIZZ2 negatively correlated with the pulmonary function [Forced Vital Capacity (FVC), Forced Expiratory Volume (FEV1), FEV1%, FEV1/FVC) (r = - 0.3086, - 0.3529, - 0.3343, and - 0.2676, respectively, p = 0.0003, p < 0.0001, p < 0.0001, p = 0.0014). The expression of human serum FIZZ2 was positively correlated with the smoking index (r = 0.2749, p = 0.0015). There was a positive correlation between the FIZZ2 concentration and the frequency of AECOPD episodes in the following year (r = 0.7291, p < 0.0001).
FIZZ2 expression was elevated in patients with COPD and its serum concentration might be a potential biomarker for AECOPD.
炎症区2发现蛋白（FIZZ2）与肺部炎症相关。本研究旨在探讨FIZZ2作为慢性阻塞性肺疾病（COPD）标志物的表达及应用价值。
采用免疫组织化学法检测COPD患者中FIZZ2的表达。通过酶联免疫吸附测定法测定FIZZ2的血清浓度，并记录次年慢性阻塞性肺疾病急性加重（AECOPD）的发作次数。
FIZZ2在支气管上皮细胞中的表达升高（0.217±0.021对0.099±0.010，p<0.0001），与肺功能（FEV1/FVC%）呈负相关（p=0.0149），与吸烟指数呈正相关（p=0.0241）。COPD患者的血清FIZZ2水平显著高于健康对照组（561.6±70.71对52.24±20.52 pg/ml，p<0.0001），且随COPD严重程度增加而升高。血清FIZZ2水平与肺功能[用力肺活量（FVC）、第一秒用力呼气容积（FEV1）、FEV1%、FEV1/FVC]呈负相关（r分别为-0.3086、-0.3529、-0.3343和-0.2676，p=0.0003、p<0.0001、p<0.0001、p=0.0014）。人血清FIZZ2的表达与吸烟指数呈正相关（r=0.2749，p=0.0015）。FIZZ2浓度与次年AECOPD发作频率呈正相关（r=0.7291，p<0.0001）。
COPD患者中FIZZ2表达升高，其血清浓度可能是AECOPD的潜在生物标志物。
